Option Care Health

Overview

Option Care Health is a national home and alternate-site infusion provider that helps pharma and biotech teams launch and support clinician-administered complex therapies through infusion pharmacy, ambulatory infusion suites, nursing, payer coordination, and manufacturer data programs. For manufacturers, its relevance is strongest when the therapy requires benefit coordination, complex handling, nurse-administered care, site-of-care management, limited-distribution access, or a national infusion footprint that can support launch consistency across markets.

Option Care Health should not be evaluated as a generic specialty pharmacy. The public site places it in the specialty-pharmacy lane only because Rx Almanac does not maintain a dedicated public infusion category; buyers should compare it against home-infusion, alternate-site infusion, and clinical-administration networks. Its current operating profile points to a single infusion-services model with roughly 90 full-service pharmacies, 111 ambulatory infusion suites, 750+ infusion chairs, 28 advanced-practitioner locations, and broad acute and chronic therapy coverage.

Infusion Capability Model

The framework below standardizes how Rx Almanac evaluates infusion capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Option Care Health is evaluated as a national home and alternate-site infusion provider with specialty pharmacy, compounding pharmacy, ambulatory infusion suite, clinical nursing, and manufacturer-service capabilities.

Capability	Buyer should compare	Option Care Health readout
Infusion footprint	Home coverage, suite access, pharmacy network, chair capacity, and target-market reach.	Core national footprint. 190+ locations, 111 ambulatory infusion suites, and 750+ chairs.
Clinical nursing	Nurse availability, training model, protocols, escalation, and continuity across home and suite settings.	Core clinical layer. Naven Health and the clinician workforce support home and suite-based care.
Benefits and reimbursement	Benefit investigation, PA, reauthorization, appeals, patient estimates, and referral-to-start speed.	Core operating workflow. Referral intake, benefit work, PA, and reauthorization are central to the model.
Complex handling	Compounding, cold chain, drug preparation, REMS, hazardous handling, and inventory controls.	Core pharmacy infrastructure. Roughly 90 full-service pharmacies support acute and chronic infusion therapies.
Manufacturer data	Referral status, start-of-care, abandonment, adherence, outcomes, and dispense visibility.	RFP diligence item. Define reporting cadence, field definitions, exceptions, and data rights.
Site-of-care strategy	Ability to move care from HOPD to home or ambulatory suites without losing clinical oversight.	Core site-of-care fit. Best when economics and patient convenience require alternate-site administration.
Specialty pharmacy adjacency	Dispensing scope, LDD access, pharmacy handoffs, and hub / SP network boundaries.	Supporting capability. LDD access and specialty dispensing support the infusion model.

Buyer Fit

• Best-fit use case: infused biologics, specialty injectables, immunoglobulin, nutrition support, anti-infectives, oncology support, autoimmune, neurology, and rare disease therapies that need home or suite administration.
• Launch motion: manufacturer + payer + provider coordination where success depends on start-of-care speed, ongoing reauthorization, clinical monitoring, limited-distribution access, and patient preference for lower-cost settings.
• Where it may be less central: oral specialty products, hub-first affordability programs, or products where dispensing can be handled by a conventional limited-distribution pharmacy network without infusion operations.
• How to diligence: compare payer access, referral conversion, time-to-start, nurse capacity, advanced-practitioner coverage, therapy-specific SOPs, data-feed maturity, and local coverage in priority launch markets.

Differentiators

• Independent national infusion scale: Option Care gives manufacturers a non-payer-owned national alternative for home and alternate-site infusion.
• Home plus ambulatory suite model: The footprint supports both in-home care and supervised suite-based administration, which matters for therapies with monitoring or patient-preference constraints.
• Clinical workforce depth: Nursing and pharmacist infrastructure can support education, administration, monitoring, and escalation beyond basic dispense operations.
• Payer and provider interface: The model sits at the intersection of payer authorization, provider referral, and patient-site coordination, which is often where infusion launches break down.
• Manufacturer program infrastructure: LDD access, enhanced service programs, and data reporting make the platform relevant to launch teams, not only provider referral sources.
• Complex therapy breadth: The platform is relevant across acute and chronic therapies, not only one therapeutic lane.

RFP Questions

• Which geographies, payer contracts, and infusion sites are actually available for this product at launch?
• What are the expected time-to-benefit-verification, time-to-authorization, and time-to-start metrics by payer and therapy type?
• Which nursing tasks, clinical monitoring steps, and adverse-event escalation processes are included in scope?
• Which advanced-practitioner sites, suite protocols, or higher-acuity pathways are available for this therapy?
• How are home infusion, ambulatory suite administration, pharmacy preparation, and specialty dispensing split operationally?
• How will the vendor coordinate with the hub, prescribers, specialty distributors, and field reimbursement teams?
• What data will be delivered to the manufacturer, at what cadence, and with which definitions for referral, start, abandonment, discontinuation, and reauthorization status?
• Which site-of-care migration assumptions should be validated by payer, geography, therapy, and administration protocol?
• Which LDD access, enhanced service program, and manufacturer reporting elements are already live versus custom-build?
• Which activities are performed by Option Care directly versus affiliates, local partners, or third-party nursing resources?

Recent Activity

• 2026-05: Current company materials continued to position Option Care Health around infusion services, nationwide distribution for pharmaceutical manufacturers, broad therapy coverage, provider referral support, payer and health-system partnerships, and accredited infusion operations.
• 2026-04: Q1 2026 materials reinforced the single infusion-services operating frame, ambulatory infusion suite growth, advanced-practitioner sites, and the importance of referral intake, authorization, reauthorization, and nursing capacity.
• 2025-08: Quince Therapeutics selected Option Care Health for U.S. administration of its lead rare disease asset, a useful example of manufacturer reliance on the platform for specialized administration.
• 2024-10: CVS Health’s exit from legacy Coram home infusion changed the competitive landscape and made scale, payer access, and national execution more important in home infusion RFPs.